Abstract
Malaria with 1 million deaths and about 500 million new cases reported annually is a challenge to drug therapy and discovery. Drug resistance accompanied by lack of progress in the development of vaccines or resistant reversal agents has further aggravated the situation. In this scenario, development of antimalarials acting by novel pathways is the best option. Decoding of the Plasmodium falciparum genome has helped scientists working in the area of drug development by providing new drug targets such as carbonic anhydrase, homocysteine hydrolase, antioxidant proteins, glutathione reductase etc. Efforts are ongoing to elucidate structures and functions of novel targets. These developments will form an important part of this review. Developments related to novel antimalarials such as Ugi adducts of chloroquine, polar derivatives of artemisinins, amino acid complexes of 8-aminoquinolines, bioimidazoles, t-butylperoxyamines etc will also be reviewed. We are working on drug discovery leading to development of novel antimalarials. A basic nucleus pyrimido-[4,5- b]quinoline was developed based on pharmacophoric studies. Appropriate substitutions on this basic nucleus taking into consideration overall basicity and lipophilicity are the prime considerations in the development of novel antimalarials. Preliminary work led to synthesis, characterization and evaluation of nine novel derivatives for antimalarial activity in mice infected with P. berghei using chloroquine as standard. Five out of nine derivatives were active and among these, three derivatives were found to be more potent than chloroquine. Encouraged by this positive outcome, additional novel derivatives are being developed. Efforts are also on to establish the likely targets with which these novel molecules interact.
Keywords: Malaria, resistance, malarial vaccine, P. falciparum genome, targets, antimalarials, pyrimidoquinolines
Anti-Infective Agents in Medicinal Chemistry
Title: Recent Developments in Antimalarial Drug Discovery
Volume: 5 Issue: 1
Author(s): A. A. Joshi and C. L. Viswanathan
Affiliation:
Keywords: Malaria, resistance, malarial vaccine, P. falciparum genome, targets, antimalarials, pyrimidoquinolines
Abstract: Malaria with 1 million deaths and about 500 million new cases reported annually is a challenge to drug therapy and discovery. Drug resistance accompanied by lack of progress in the development of vaccines or resistant reversal agents has further aggravated the situation. In this scenario, development of antimalarials acting by novel pathways is the best option. Decoding of the Plasmodium falciparum genome has helped scientists working in the area of drug development by providing new drug targets such as carbonic anhydrase, homocysteine hydrolase, antioxidant proteins, glutathione reductase etc. Efforts are ongoing to elucidate structures and functions of novel targets. These developments will form an important part of this review. Developments related to novel antimalarials such as Ugi adducts of chloroquine, polar derivatives of artemisinins, amino acid complexes of 8-aminoquinolines, bioimidazoles, t-butylperoxyamines etc will also be reviewed. We are working on drug discovery leading to development of novel antimalarials. A basic nucleus pyrimido-[4,5- b]quinoline was developed based on pharmacophoric studies. Appropriate substitutions on this basic nucleus taking into consideration overall basicity and lipophilicity are the prime considerations in the development of novel antimalarials. Preliminary work led to synthesis, characterization and evaluation of nine novel derivatives for antimalarial activity in mice infected with P. berghei using chloroquine as standard. Five out of nine derivatives were active and among these, three derivatives were found to be more potent than chloroquine. Encouraged by this positive outcome, additional novel derivatives are being developed. Efforts are also on to establish the likely targets with which these novel molecules interact.
Export Options
About this article
Cite this article as:
Joshi A. A. and Viswanathan L. C., Recent Developments in Antimalarial Drug Discovery, Anti-Infective Agents in Medicinal Chemistry 2006; 5 (1) . https://dx.doi.org/10.2174/187152106774755626
DOI https://dx.doi.org/10.2174/187152106774755626 |
Print ISSN 1871-5214 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6018 |
Related Articles
-
<i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Physicochemical Properties and Photochemical Reactions in Organic Crystals
Current Organic Chemistry Update on the Slow Delayed Rectifier Potassium Current (IKs): Role in Modulating Cardiac Function
Current Medicinal Chemistry A Systematic in-silico Analysis of Helicobacter pylori Pathogenic Islands for Identification of Novel Drug Target Candidates
Current Genomics Sleep Loss and Hypertension: A Systematic Review
Current Pharmaceutical Design ENaC Regulation by Proteases and Shear Stress
Current Molecular Pharmacology Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry "Neuro-Semeiotics" and "Free-Energy Minimization" Suggest a Unified Perspective for Integrative Brain Actions: Focus on Receptor Heteromers and Roamer Type of Volume Transmission
Current Protein & Peptide Science Structure-Based Drug Design of Peptide Mimetics Containing Large P3 Moieties as Inhibitors of Factor VIIa
Letters in Drug Design & Discovery Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca
Current Drug Abuse Reviews A Review of Preclinical Research Demonstrating that Drug and Non-Drug ReinforcersDifferentially Affect Behavior
Current Drug Abuse Reviews How to Achieve Near Zero Fluoroscopy During Radiofrequency Ablation of Atrial Fibrillation: A Strategy Used at Two Centers
Current Cardiology Reviews Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Psychopharmacotherapy of Obsessive-Compulsive Symptoms within the Framework of Tourette Syndrome
Current Neuropharmacology Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design